Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) trading capacity remained 1.51 million shares during the last session. Dai Ichi Life Insurance Company Ltd's holdings in Vertex Pharmaceuticals were worth $3,732,000 as of its most recent SEC filing. Guardian Life Insurance Co. of America lifted its position in shares of Vertex Pharmaceuticals by 0.6% during the first quarter. Manning And Napier Advsrs Limited Company accumulated 2.13M shares or 1.02% of the stock. Jennison Associates LLC increased its stake in shares of Vertex Pharmaceuticals by 74.2% in the third quarter. The stock was trading on below-average volume. Finally, Morgan Stanley increased its stake in shares of Vertex Pharmaceuticals by 269.3% in the third quarter.
Shares of Vertex Pharmaceuticals (NASDAQ:VRTX) traded up 0.01% during mid-day trading on Friday, hitting $86.73. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post $1.60 EPS for the current year. About shares traded. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) has risen 45.69% since September 12, 2016 and is uptrending. Finally, Buckingham Asset Management LLC lifted its position in shares of Vertex Pharmaceuticals by 3.6% during the second quarter. Also, EVP Stuart A. Arbuckle sold 1,208 shares of the company's stock in a transaction that occurred on Wednesday, November 9th. Institutional investors and hedge funds own 92.88% of the company's stock. The shares were sold at an average price of $160.93, for a total value of $4,606,621.25. Following the transaction, the senior vice president now owns 22,648 shares in the company, valued at $3,020,337.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website.
In other Vertex Pharmaceuticals news, CMO Jeffrey Chodakewitz sold 5,157 shares of the stock in a transaction that occurred on Wednesday, June 21st. Following the transaction, the chief marketing officer now directly owns 127,668 shares in the company, valued at $16,963,247.16. The disclosure for this sale can be found here. In the last quarter, insiders sold 526,092 shares of company stock valued at $84,101,702.
A number of other analysts have also recently weighed in on VRTX. Raymond James Financial, Inc. upgraded Vertex Pharmaceuticals from a "market perform" rating to an "outperform" rating and set a $181.00 price target on the stock in a report on Wednesday, July 19th.
Army Denies Invading Kanu's Home
While speaking with journalists, Kanu said the soldiers , loaded in an armoured tank and three Hilux vans shot his supporters. The soldiers reportedly claimed they had seen someone taking pictures of them from the NUJ building.
07/19/2017 - Vertex Pharmaceuticals Incorporated had its "buy" rating reiterated by analysts at Stifel Nicolaus. Jefferies Group LLC reissued a "buy" rating and issued a $126.00 target price on shares of Vertex Pharmaceuticals in a research note on Friday, June 9th. Zacks Investment Research raised shares of Vertex Pharmaceuticals from a "strong sell" rating to a "hold" rating in a research report on Monday, October 31st. Equity research analysts have given opinions on where they foresees the stock level. The stock presently has an average rating of "Buy" and an average price target of $162.88.
WARNING: This piece was originally published by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this story on another website, it was illegally copied and reposted in violation of USA & worldwide copyright & trademark legislation. The correct version of this piece can be read at https://stocknewstimes.com/2017/09/12/westpac-banking-corp-sells-17855-shares-of-vertex-pharmaceuticals-incorporated-vrtx.html.
Vertex Pharmaceuticals Incorporated (VRTX) has a Return on Assets of 8.8 percent, Return on Investment of -0.3 percent and a Return on Equity of 19.4 percent. The firm has a market cap of $39.54 billion, a P/E ratio of 150.64 and a beta of 1.75. Vertex Pharmaceuticals has a 52-week low of $71.46 and a 52-week high of $167.85. The firm's 50 day moving average price is $155.29 and its 200 day moving average price is $125.51. ALTSHULER DAVID sold $20,701 worth of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) on Monday, May 15. Vertex Pharmaceuticals had a net margin of 12.05% and a return on equity of 4.64%. The firm had revenue of $544.10 million during the quarter, compared to the consensus estimate of $489.95 million. During the same period in the previous year, the company earned $0.17 EPS. The Baker Bros Advisors Lp holds 4.58 million shares with $59.66 million value, up from 100,000 last quarter.
Vertex Pharmaceuticals Incorporated is engaged in discovering, developing, manufacturing and commercializing medicines for serious diseases.
- Travailleurs détachés: Juncker veut une "autorité commune" de l'UE
- Russell Investments Group Ltd. Sells 12040 Shares of Control4 Corporation (CTRL)
- College Park Will Allow Non-Citizens to Vote in Local Elections
- De Bruyne's Manchester City masterclass delights Guardiola
- Un nouveau tatouage jusqu'aux fesses pour Coeur de Pirate
- Hurricane Irma: Floridians begin seeking shelter as storm strengthens
- The Top Three Holders Of Banco Bradesco SA (BBD)
- Hyde Park man critically wounded in Boston Common shooting
- Saudi Arabia rejects call for independent United Nations probe into Yemen
- Domino's Pizza Lifted to "Buy" By Research Firm Zacks